Training and Resources
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal and GEJ carcinoma
KEYTRUDA® (pembrolizumab) KEYNOTE-590 clinical data presentation
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Oesophageal cancer Q&A with Professor Jeff Evans
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Pembrolizumab plus chemotherapy oesophageal cancer patient case studies in adenocarcinoma
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYTRUDA® in combination with chemotherapy
A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated events
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYTRUDA mode of action
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
PD-L1 testing and CPS interpretation in oesophageal cancer
Patient education and support materials
CPS = Combined Positive Score; GEJ = Gastroesophageal Junction.
More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal cancer
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
